Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Physiomics secures contract with Numab Therapeutics

Tue, 11th May 2021 10:46
(Sharecast News) - Consultancy firm Physiomics said on Tuesday that it has been awarded a first contract with new client Numab Therapeutics.
Physiomics noted it has "recent significant experience" in the mathematical modelling of multi-specific pharmaceuticals, which it will use to work on an undisclosed compound as part of Numab's project, which was expected to last "around three months".

The AIM-listed group added that Numab was an "exciting young biopharmaceutical company" based in Zurich, Switzerland which develops "multi-specific biotherapeutics" for chronic inflammation and cancer.

Chief executive Dr Jim Millen said: "We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team."

As of 1045 BST, Physiomics shares were up 2.56% at 6.0p. Physiomics

Shares in this article

Related News

Physiomics reports strong operational progress
5 days ago

Physiomics reports strong operational progress

(Sharecast News) - Physiomics said on Friday that it was making strong operational progress and building the largest commercial pipeline in its histor...

Physiomics reports strong operational progress
5 days ago

Physiomics reports strong operational progress

(Sharecast News) - Physiomics said on Friday that it was making strong operational progress and building the largest commercial pipeline in its histor...

Physiomics hails progress despite one-off costs to replace board
5 days ago

Physiomics hails progress despite one-off costs to replace board

(Alliance News) - Physiomics PLC on Friday said it "continues to make strong operational progress" but noted one-off costs from the dismissal of its p...